Effects of tumor necrosis factor-like ligand 1A (TL1A) on imiquimod-induced psoriasiform skin inflammation in mice

Lin, Li; Fu, Lianshe; Zhou, Peimei; Lu, Yiming; Zhang, Liwen; Wang, Wenju; Nie, Jianjun; Zhang, Dawei; Liu, Yan; Wu, Bo; Chen, Tao

doi:10.1007/s00403-019-02030-8

Cited by 7 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TL1A, also known as vascular endothelial growth inhibitor (VEGI)-251 or TNFSF15, is the only proven ligand for DR3 to date ( 5 ). TL1A is a single-pass type II transmembrane protein encoded by the Tnfsf15 gene on chromosome 4 in mice and 9q32 in humans ( 4 ).…”

Section: Expression and Composition Of Tl1a And Dr3mentioning

confidence: 99%

“…TL1A is a single-pass type II transmembrane protein encoded by the Tnfsf15 gene on chromosome 4 in mice and 9q32 in humans ( 4 ). Similar to other TNFSF cytokines, membrane-bound TL1A can be cleaved by alternative splicing or through TNF-α-converting enzyme, and is shed from the extracellular domain to form soluble TL1A (sTL1A) ( 4 , 5 , 27 ). Notably, sTL1A may continue to efficiently activate DR3.…”

Section: Expression and Composition Of Tl1a And Dr3mentioning

confidence: 99%

“…Additionally, the expression of TL1A on DCs and macrophages is increased upon activation via the receptor for the Fc region of IgG (FcγR) and Toll-like receptors (TLRs), including TLR2 and TLR4, while expression of TL1A on endothelial cells may be enhanced by interleukin-1 beta (IL-1β) and TNF-α stimulation ( 15 ). Nevertheless, chondrocytes, synovial fibroblasts, tissue macrophages and lamina propria lymphocytes also express TL1A at low levels under conditions of inflammation or upon stimulation ( 5 , 6 ). Therefore, the binding of TL1A to DR3 triggers signal transduction and exerts pro- and anti-inflammatory functions.…”

Section: Expression and Composition Of Tl1a And Dr3mentioning

confidence: 99%

“…The DR3/TL1A pathway has been clearly implicated in several diseases, including allergic lung inflammation ( 35 ), psoriasis ( 5 ), IBD ( 4 ) and rheumatoid arthritis ( 43 ). The aforementioned diseases share a common molecular mechanism in which DR3 signaling exerts pleiotropic effects on the activation, differentiation, proliferation and cytokine release of ILC2s and T helper cells (including Th1, Th2, Th9 and Th17 cells).…”

Section: Co-stimulation Of Effector Immune Cellsmentioning

confidence: 99%

See 3 more Smart Citations

Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)

Yu¹,

Jiang²,

Sun³

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Section: Expression and Composition Of Tl1a And Dr3mentioning

confidence: 99%

Section: Expression and Composition Of Tl1a And Dr3mentioning

confidence: 99%

Section: Expression and Composition Of Tl1a And Dr3mentioning

confidence: 99%

Section: Co-stimulation Of Effector Immune Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)

Yu¹,

Jiang²,

Sun³

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

“…Epidermal thickness was measured by selecting 10 random regions from skin sections of each mouse using 10 × magni cation. We used baker's scores to judge pathological manifestations of psoriasis [9] : Munro's small abscess was found in the stratum corneum, 2.0 point; hyperkeratosis, 0. PBST for 3 times with an incubation period of 5 min in the solution every time.…”

Section: Histologymentioning

confidence: 99%

Gancao Nurish-Yin Decoction Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesions and Inflammation in Mice

Chen¹,

Wu²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundPsoriasis is an autoimmune skin disease with a high clinical prevalence, which is often poses treatment difficulties. In this study, we tested whether Gancao nurish-Yin (GNY) decoction is effective for treating mice with imiquimod (IMQ)-induced psoriasis-like skin lesions. MethodsMice were divided into 4 groups including healthy control group, model group (IMQ-induced psoriasis mice), and two psoriasis induced groups of mice treated with GNY-2.5g/kg and GNY-5g/kg given in the drinking water (n = 8/group). Psoriasis area and severity index (PASI) was used to monitor psoriatic symptoms. H&E staining of dermis and baker’s scores were used to evaluate disease severity. Inflammatory cells positive for Gr-1, CD11c, RORγt and TGF-β were counted by using immunohistochemistry or immunofluorescence staining methods. Flow cytometry was used to analyse CD4+CD17+ Th17 cells, and CD25+Foxp3+ Tregs within splenocyte cell population. Relative mRNA expression of IL-6, IL-10, IL-17A, IL-22, IL-23, TNF-ɑ, TGF-β and AMPKɑ1 in the dermis was was semi-quatified using qPCR. ResultsCompared to model group, GNY decoction treated mice, at both the concentrations, improved morphological features, as demonstrated by PASI scores and decreased levels of hyperproliferating keratinocytes. GNY decoction at a higher concentration significantly decreased Gr-1, CD11c, RORγt and TGF-β positive cells in the dermis as well as the differentiated CD4+CD17+ Th17 cells, whereas, CD25+Foxp3+ Tregs were increased in the spleen, mainly with low dose GNY decoction. Furthermore, relative mRNA expression of IL-6, IL-10, IL-17A, IL-22, IL-23, TNF-ɑ, TGF-β and AMPKɑ1 within dermis were elevated in mice from IMQ model group, which were significantly recduced in mice treated with GNY decoction at GNY-5g/kg concentration.ConclusionHere we demonstrate disease ameliorating effects of GNY decoction in IMQ-induced psoriasis-like skin lesions in mice, which could form basis for considering GNY decoction for treatment of psoriasis patients.

show abstract

Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments

et al. 2021

View full text Add to dashboard Cite

Effects of tumor necrosis factor-like ligand 1A (TL1A) on imiquimod-induced psoriasiform skin inflammation in mice

Cited by 7 publications

References 22 publications

Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)

Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)

Gancao Nurish-Yin Decoction Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesions and Inflammation in Mice

Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments

Contact Info

Product

Resources

About